Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Clinical trial NCT04774068 · COMPLETED

Trial details

NCT number: NCT04774068
Sponsor: Walter Hanel
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Anaplastic Large Cell Lymphoma Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Transformed Mycosis Fungoides Refractory Anaplastic Large Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Transformed Mycosis Fungoides T-Cell Non-Hodgkin Lymphoma

Start date: 2021-09-01
Primary completion: 2024-10-27
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.